In February 2022, Oncorena announced the initiation of the Phase I/II clinical trial of ONC175 (orellanine), Oncorella-1, at The Centre for Clinical Cancer Studies at the Karolinska University Hospital in Stockholm, Sweden. The first patient was given an infusion of ONC175 for 30 minutes in August 2023 and more patients are ready to be treated.
The clinical study is conducted at the Centre for Clinical Cancer Studies at the Karolinska University Hospital in Stockholm, Sweden, and studies safety, tolerability, pharmacokinetics, and signs of anti-tumor effects in treatment with ONC175. After the treatment each patients’ results are followed up four weeks after the infusion by an independent Data Review Committee recommending potential dose escalations.
The Phase I-II study enrolls up to 40 patients with metastatic renal cancer on dialysis due to renal failure from Sweden and may include patients from other countries as well. Since the patients are dialysis-dependent, hemo-dialysis is provided in collaboration with a team at the dialysis unit at the Karolinska University Hospital. The study is coordinated together with a clinical research organization specialist in oncology clinical trials.
The drug candidate ONC175, with a unique mode of action, is being developed for organ-specific chemotherapy with curative potential for patients with metastatic renal cancer undergoing dialysis due to kidney failure. Preclinical evidence shows that ONC175 specifically exerts powerful anti-tumor effects on metastatic kidney cancer in different preclinical models.
Oncorena sees a great medical need for improved treatment options in patients with metastatic renal cancer undergoing dialysis. The expectations are that the results from the study will be of great benefit to patients in the future.
We are looking for patients who suffer from advanced Renal Cancer and would like to participate in a clinical trial to test a new potential treatment. The objective of the study is to evaluate the safety, tolerability, and anti-tumor efficacy of ONC175 (orellanine) treatment in patients with Metastatic Clear-Cell or Papillary Renal Cell Carcinoma. Find out more about the trial and check your or your candidate’s eligibility here: